CFO transition
Yarrow Bioscience, Inc. CFO transition: Tyler Zeronda to succeed Mutya Harsch
Yarrow Bioscience, Inc. reported in a Form 8-K filed July 28, 2026 that Tyler Zeronda will succeed Mutya Harsch as Chief Financial Officer, effective July 27, 2026.
In the filing's words
On July 27, 2026, the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Yarrow Bioscience, Inc. (VYNE) |
|---|---|
| Event | Transition |
| Incoming | Tyler Zeronda |
| Outgoing | Mutya Harsch |
| Title in the filing | Chief Financial Officer |
| Effective | July 27, 2026 |
| 8-K filed | July 28, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer and Treasurer, VYNE Therapeutics Inc. (Nasdaq: VYNE) |
| SEC CIK | 0001566044 |
Yarrow Bioscience, Inc. reported this change in a Form 8-K, Item 5.02, filed July 28, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Tyler Zeronda? Send a correction with the primary source.